z-logo
open-access-imgOpen Access
[1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains
Author(s) -
O. Fedorov,
Hannah Lingard,
Christopher Wells,
Octovia Monteiro,
S. Picaud,
Tracy Keates,
Clarence Yapp,
Martin Philpott,
Sarah Martin,
I. Felletar,
Brian D. Marsden,
P. Filippakopoulos,
Susanne Müller,
Stefan Knapp,
Paul E. Brennan
Publication year - 2013
Publication title -
journal of medicinal chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.01
H-Index - 261
eISSN - 1520-4804
pISSN - 0022-2623
DOI - 10.1021/jm401568s
Subject(s) - bromodomain , brd4 , chemistry , drug discovery , stereochemistry , structure–activity relationship , subfamily , combinatorial chemistry , acetylation , computational biology , biochemistry , in vitro , biology , gene
Bromodomains are gaining increasing interest as drug targets. Commercially sourced and de novo synthesized substituted [1,2,4]triazolo[4,3-a]phthalazines are potent inhibitors of both the BET bromodomains such as BRD4 as well as bromodomains outside the BET family such as BRD9, CECR2, and CREBBP. This new series of compounds is the first example of submicromolar inhibitors of bromodomains outside the BET subfamily. Representative compounds are active in cells exhibiting potent cellular inhibition activity in a FRAP model of CREBBP and chromatin association. The compounds described are valuable starting points for discovery of selective bromodomain inhibitors and inhibitors with mixed bromodomain pharmacology.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom